Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
On/Off Study of missed doses of atomoxetine or OROS methylphenidate in stable pediatric ADHD
NL-OMON36754Phase 4Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of atomoxetine and methylphenidate in attention deficit hyperactivity disorder (ADHD) (2 cohorts), sponsored by Eli Lilly and Company. Started Jun 2010; status: active, not recruiting.
02
Drugs
atomoxetinemethylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NL-OMON36754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36754.